176 related articles for article (PubMed ID: 38241591)
1. Recent advances and remaining challenges in lung cancer therapy.
Barr T; Ma S; Li Z; Yu J
Chin Med J (Engl); 2024 Mar; 137(5):533-546. PubMed ID: 38321811
[TBL] [Abstract][Full Text] [Related]
2. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party.
Lu C; Tan Y
Mol Ther Oncol; 2024 Mar; 32(1):200773. PubMed ID: 38596295
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy - new perspective in lung cancer.
Pinheiro FD; Teixeira AF; de Brito BB; da Silva FAF; Santos MLC; de Melo FF
World J Clin Oncol; 2020 May; 11(5):250-259. PubMed ID: 32728528
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Awareness, Palliative Care Use, and Barriers to Palliative Care in Patients Undergoing Immunotherapy or Chemo-Immunotherapy for Metastatic Lung Cancer.
McLouth LE; Gabbard J; Levine BJ; Golden SL; Lycan TW; Petty WJ; Weaver KE
J Palliat Med; 2023 Jun; 26(6):831-836. PubMed ID: 36912809
[No Abstract] [Full Text] [Related]
5. Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review.
Guo H; Zhang J; Qin C; Yan H; Luo X; Zhou H
Medicine (Baltimore); 2024 Jan; 103(3):e36861. PubMed ID: 38241591
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.
Wu C; Li W; Tao H; Zhang X; Xin Y; Song R; Wang K; Zuo L; Cai Y; Wu H; Hui W
Crit Rev Oncol Hematol; 2024 Jan; 193():104195. PubMed ID: 37931769
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.
Boussageon M; Swalduz A; Chouaïd C; Bylicki O
BioDrugs; 2022 Mar; 36(2):137-151. PubMed ID: 35147894
[TBL] [Abstract][Full Text] [Related]
10. First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
Reck M; Remon J; Hellmann MD
J Clin Oncol; 2022 Feb; 40(6):586-597. PubMed ID: 34985920
[TBL] [Abstract][Full Text] [Related]
11. In Vitro 3D Spheroid Model Preserves Tumor Microenvironment of Hot and Cold Breast Cancer Subtypes.
Dhandapani H; Siddiqui A; Karadkar S; Tayalia P
Adv Healthc Mater; 2023 Aug; 12(21):e2300164. PubMed ID: 37141121
[TBL] [Abstract][Full Text] [Related]
12. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.
de Visser KE; Joyce JA
Cancer Cell; 2023 Mar; 41(3):374-403. PubMed ID: 36917948
[TBL] [Abstract][Full Text] [Related]
13. NK cells and solid tumors: therapeutic potential and persisting obstacles.
Tong L; Jiménez-Cortegana C; Tay AHM; Wickström S; Galluzzi L; Lundqvist A
Mol Cancer; 2022 Nov; 21(1):206. PubMed ID: 36319998
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
